Peptides for Longevity: the 2026 Evidence Map

Longevity research has moved beyond resveratrol headlines and metformin re-purposing. The compounds being studied seriously in 2026 share a different shape: short peptides and peptide-adjacent molecules that act at specific cellular bottlenecks, from mitochondrial energy production to telomere maintenance to NAD+ recycling. None of them is a longevity pill. All of them sit somewhere on a credibility scale that runs from "FDA-approved for a non-longevity indication" to "preclinical with limited human data." This pillar maps that scale.

Key takeaways#

• The peptide longevity catalogue in 2026 has four anchor compounds with the strongest mechanistic case: NAD+ precursors, MOTS-c, Epitalon, and SS-31 (elamipretide). Each targets a distinct aging mechanism.
• Mechanism is not enough on its own. A clean preclinical signal becomes a credible longevity claim only when human pharmacokinetics, safety profile, and at least one trial endpoint replicate.
• The cluster splits cleanly into "in-human data exists" (NAD+, SS-31) and "mostly preclinical with translational gaps" (MOTS-c, Epitalon). The decision rule is which gap a reader is comfortable with.
• Regulatory status differs in ways that change accessibility: SS-31 (elamipretide, sold as Forzinity) is FDA-approved for Barth syndrome only; NAD+ is compounded on prescription in the US under an FDA interim policy; MOTS-c and Epitalon are not approved anywhere in the US or EU. Since October 30, 2026 a draft HHS enforcement-discretion policy lets US 503A pharmacies compound MOTS-c acetate and Epitalon acetate by injection on a patient-specific prescription, one active ingredient per product; that is not FDA approval.
• Klarovel does not sell, source, or fulfil peptides. The catalogue here is the protocol and education layer.

How aging research reframed the peptide question#

Twentieth-century longevity research focused on calorie restriction and the secondary signalling pathways it triggers: mTOR, sirtuins, AMPK. Peptides entered the conversation when researchers started identifying short signalling molecules that hit the same pathways without requiring the patient to eat less. Some are endogenous fragments of larger mitochondrial-derived proteins. Others are synthetic analogues of compounds first characterised in the 1960s for completely different indications.

What unifies them mechanistically: each works on a cellular bottleneck that age progressively narrows. NAD+ falls with age, and falling NAD+ slows the sirtuin-mediated DNA repair that protects against cancer and accumulated damage. Mitochondrial membrane integrity degrades, and the cardiolipin-binding peptide SS-31 stabilises it. Telomeres shorten with each replication, and Epitalon has been shown to influence telomerase expression. MOTS-c, a small peptide encoded inside the mitochondrial genome itself, acts as a metabolic signalling hormone that drops as humans age. A peer-reviewed overview in Trends in Endocrinology and Metabolism frames mitochondrial-derived peptides as a new class of metabolic regulators worth studying for age-related disease.

The honest framing: this is one of the most promising mechanistic stories in longevity biology. It is also where overclaiming runs ahead of human data faster than almost anywhere else in the peptide field.

NAD+ peptides and precursors: the energy-recycling axis#

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme that powers sirtuins, the NAD+-dependent enzymes most strongly linked to mammalian lifespan extension, and it also fuels PARP-driven DNA repair. Tissue NAD+ falls steadily across adult life and falls faster in metabolic stress. Restoring it is the most heavily-studied longevity intervention in the catalogue, with multiple human trials using oral precursors (NR, NMN) and direct injection. NNMT inhibition is a related route to NAD+ availability, covered separately in the NNMT inhibitor guide.

The injection route is what has pulled NAD+ into the peptide conversation. NAD+ infusion clinics report subjective benefits in fatigue and cognitive clarity. Published evidence for injection-route NAD+ is thinner than for oral precursors, but the underlying biology is the same: a molecule that the body recognises, processed by enzymes whose function is well-characterised. The NAD+ peptide guide walks through the trial data, the route comparison, and the gap between subjective reports and measured endpoints.

What the published research actually shows: oral NR raises blood NAD+ measurably and consistently. The translation from "raised NAD+" to "extended healthspan" is the bridge that remains unproven in humans, but the bridge in mice is sturdy enough to sustain a growing set of human trials of NAD+ precursors. For the injectable route, both the pharmacokinetics and the clinical endpoint case are still being built.

The first published human pharmacokinetic study of intravenous NAD+ is a useful corrective to the "faster is better" story. In Grant et al. (2019), eight healthy men received 750 mg of NAD+ over 6 hours: plasma NAD+ did not rise at all for the first 2 hours, because the infused NAD+ was cleared from the blood as fast as it arrived, and it peaked about 4-fold above baseline only at the end of the infusion.

MOTS-c: the mitochondrial peptide hormone#

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome, discovered in 2015. The discovery itself reframed mitochondrial biology: until then, mitochondrial DNA was understood to encode only the proteins involved in oxidative phosphorylation. The recognition that mitochondria also encode signalling peptides created a new class of metabolic regulators.

Functionally, MOTS-c has been shown to act as a hormone that the mitochondria release in response to metabolic stress. It signals to muscle tissue to improve insulin sensitivity, to the liver to constrain glucose output, and to the immune system in ways that are still being characterised. Importantly, circulating MOTS-c levels fall with age, and the deficit appears to correlate with metabolic-syndrome markers. A foundational paper in Cell Metabolism lays out the discovery and the metabolic effects in mice; the age-related decline in circulating levels comes from later human cohort work.

The human research catch-up is incomplete. Mouse models showed striking metabolic and exercise-performance effects, including muscle preservation during age-related decline. In humans the interventional data is for an analog, not MOTS-c itself: CB4211, a modified MOTS-c, completed a small randomized, placebo-controlled phase 1a/1b trial in healthy adults and adults with fatty liver disease (NCT03998514). FDA's July 2026 review for the compounding committee found no published human data on MOTS-c itself by any route, and noted that its molecular targets are still unknown (FDA, 2026). MOTS-c is also on the WADA Prohibited List, which matters for tested athletes. The MOTS-c complete guide walks through the preclinical case in detail and is explicit about where the human translation gaps remain.

Epitalon: the telomerase-adjacent tetrapeptide#

Epitalon is a synthetic four-amino-acid peptide developed in Russia in the late 1980s by Vladimir Khavinson's group, designed from the amino acid composition of Epithalamin, a bovine pineal-gland extract. Its core claim, that it influences telomerase activity, makes it one of the most-discussed and least-validated compounds in the longevity catalogue.

Russian research has published telomere-length and lifespan data in mice that, on its face, looks remarkable. Western indexed-journal replication is what is missing. The published Russian literature is real, but is largely single-centre, Russian-language, and not powered the way modern intervention trials are powered. A pillar-eligible discussion has to engage with both the mechanistic plausibility and the absence of Phase 2/3 human data on hard endpoints. The Epitalon complete guide handles that balance, mechanism then evidence then gaps.

Klarovel's editorial position on Epitalon: the mechanistic story is interesting, and the gap is human data. FDA's July 2026 review found three human studies of Epitalon (two sublingual studies in night-shift workers and one eye injection study in retinitis pigmentosa), no pharmacokinetic data, and no clinical safety data for the subcutaneous route most people use. It also flagged a theoretical cancer concern that follows from the mechanism itself: a compound that activates telomerase and lengthens telomeres needs long-term safety follow-up (FDA, 2026). Adults who choose to engage with Epitalon should do so understanding that the clinical evidence base does not match what is available for, say, semaglutide.

SS-31 (elamipretide): the mitochondrial cardiolipin stabiliser#

SS-31, also known by the development name elamipretide, is the most clinically advanced compound in the longevity-adjacent catalogue. It is a four-amino-acid peptide that binds cardiolipin, a lipid specific to the inner mitochondrial membrane, and stabilises membrane structure under oxidative stress.

The clinical pipeline is what separates SS-31 from the rest of this cluster. On 19 September 2025 the FDA granted elamipretide (Forzinity) accelerated approval to improve muscle strength in Barth syndrome, a rare genetic cardiolipin disorder, at 40 mg subcutaneously once daily in patients weighing at least 30 kg (FDA label). The randomized Barth trial missed its primary endpoints; the approval rests on knee extensor strength in the open-label extension, and a confirmatory trial is required. Elsewhere the record is mixed: the phase 2 PROGRESS-HF trial in heart failure with reduced ejection fraction missed its 4-week primary endpoint, the phase 3 MMPOWER-3 trial in primary mitochondrial myopathy missed both primary endpoints, the phase 2 dry AMD trial missed its primary endpoints, and phase 3 dry AMD trials are running.

For the longevity reader: SS-31 is the cluster member where a real clinical-trial machine has actually engaged. The SS-31 elamipretide guide walks through which indications are which, what the trials actually showed, and where the longevity case stands relative to the disease-specific case.

How to think about the longevity-peptide stack#

The temptation in this cluster is to combine all four compounds. The honest framing: nobody has trialled a four-compound stack in humans. Each peptide above has its own mechanism, its own dosing schedule, and its own monitoring requirements. A serious longevity protocol uses one or two compounds with the strongest evidence, monitors the response, and adjusts based on measurable biomarkers (NAD+ blood levels for NAD precursors, exercise performance and metabolic markers for MOTS-c).

The biomarker question is where Klarovel's protocol layer earns its keep. The are peptides safe pillar covers the sourcing and contraindication side of the conversation. The protocol layer pulls health-profile inputs and matches compounds to evidence quality and the user's risk tolerance.

What this cluster is not: it is not a substitute for the proven longevity interventions that already work. Exercise, sleep, nutrition, and the absence of smoking move all-cause mortality further than any peptide currently in trial. Peptides for longevity are an additive consideration on top of those foundations, not a replacement.

What comes next#

The pillar is a starting map, not the protocol. Each spoke in this cluster goes deeper into the mechanism, the trial data, and the protocol logic for the individual compound. Sleep, exercise, and the metabolic foundation are still the load-bearing levers; peptides are an additive layer that the research is still building.

If you want Klarovel to translate your profile and goals into a protocol that engages with this cluster honestly, start at the 12-minute questionnaire. The protocol layer matches your health data to peptides at the right evidence quality, not the loudest marketing.

• 5-Amino-1MQ Guide: What the NNMT Evidence Actually Shows: 5-Amino-1MQ is sold for fat loss, but every published result is preclinical.
• Epitalon peptide: the longevity tetrapeptide explained: Epitalon is a tetrapeptide associated with telomerase activity and pineal-gland regulation.
• Epitalon vs NAD+: Which Longevity Path Fits You (2026): Epitalon activates telomerase on short cycles; NAD+ precursors refill a daily metabolic cofactor.
• MOTS-c Peptide: Complete Guide to the Mitochondrial Mitokine: A research-based guide to MOTS-c, the mitochondrial-derived peptide studied as an exercise mimetic for metabolic health, AMPK signaling, and longevity.
• MOTS-C peptide dosage chart: doses, cycles and goals: A MOTS-C peptide dosage chart by experience level: starting dose, target, ceiling and frequency from Klarovel's curated dose table, plus timing and cycle.
• NAD+ therapy: injection mechanism, evidence, and dosing: NAD+ is the coenzyme powering cellular energy metabolism, and injectable NAD+ anchors many longevity protocols.
• SS-31 Peptide: The Mitochondrial Longevity Angle Explained: SS-31 (elamipretide) targets cardiolipin to restore mitochondrial function.